Synopsis
Synopsis
0
VMF
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-(17-(acetoyl)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)pyrrolidinium
2. Androstane-3,17-diol, 2-(4-morpholinyl)-16-(1-(2-propen-1-yl)-1-pyrrolidiniumyl)-, 17-acetate, (2beta,3alpha,5alpha,16beta,17beta)-
3. Esmeron
4. Esmerone
5. Org 9426
6. Org-9426
7. Org9426
8. Pyrrolidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)-, Bromide
9. Rocuronium
10. Zemuron
1. 119302-91-9
2. Zemuron
3. Esmeron
4. Rocuronium (bromide)
5. Org 9426
6. Org-9426
7. Chebi:8885
8. I65mw4ofhz
9. 1-allyl-1-(3alpha,17beta-dihydroxy-2beta-morpholino-5alpha-androstan-16beta-yl)pyrrolidinium Bromide, 17-acetate
10. [(2s,3s,5s,8r,9s,10s,13s,14s,16s,17r)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl] Acetate;bromide
11. Pyrrolidinium, 1-[(2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl]-1-(2-propenyl)-, Bromide
12. Rocuronium Hydrobromide
13. 1-[17b-(acetyloxy)-3a-hydroxy-2b-(4-morpholinyl)-5a-androstan-16b-yl]-1-(2-propenyl)pyrrolidinium Bromide
14. Pyrrolidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)-, Bromide
15. Ncgc00167433-01
16. Unii-i65mw4ofhz
17. Org9426
18. Eslax
19. Rocuroniumbromide
20. Zemuron (tn)
21. Mfcd00867768
22. Rocuronium Bromide [usan:usp:inn:ban]
23. Rocuronium Bromide - Ep
24. Dsstox_cid_3566
25. Org 9426 (bromide)
26. Dsstox_rid_77083
27. Dsstox_gsid_23566
28. Schembl41320
29. (+)-rocuronium Bromide
30. Rocuronium Bromide [mi]
31. Chembl1200648
32. Dtxsid7023566
33. Rocuronium Bromide [inn]
34. Rocuronium Bromide [jan]
35. Rocuronium Bromide [usan]
36. Hms3884o13
37. Rocuronium Bromide [vandf]
38. Rocuronium Bromide [mart.]
39. Rocuronium Bromide (jan/usp/inn)
40. Rocuronium Bromide [usp-rs]
41. Rocuronium Bromide [who-dd]
42. Tox21_112437
43. Bdbm50248153
44. S1397
45. Akos025149635
46. Ac-2004
47. Ccg-270222
48. Cs-1467
49. Rocuronium Bromide [orange Book]
50. Rocuronium Bromide [ep Monograph]
51. 1-((2s,3s,5s,8r,9s,10s,13s,14s,16s,17r)-17-acetoxy-3-hydroxy-10,13-dimethyl-2-morpholinohexadecahydro-1h-cyclopenta[a]phenanthren-16-yl)-1-allylpyrrolidin-1-ium Bromide
52. 111ge014
53. As-13323
54. Br177300
55. Hy-17440
56. Rocuronium Bromide [usp Monograph]
57. Bcp0726000028
58. Cas-119302-91-9
59. R0099
60. D00765
61. Q-101010
62. Q27108171
63. Rocuronium Bromide, >=98% (perchloric Acid Titration)
64. Rocuronium Bromide, European Pharmacopoeia (ep) Reference Standard
65. Rocuronium Bromide, United States Pharmacopeia (usp) Reference Standard
66. Rocuronium For Peak Identification, European Pharmacopoeia (ep) Reference Standard
67. (2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-morpholin-4-yl-16-(1-prop-2-en-1-ylpyrrolidinium-1-yl)androstane Bromide
68. 1-((2s,3s,8r,9s,10s,13s,14s,16s,17r)-17-acetoxy-3-hydroxy-10,13-dimethyl-2-morpholinohexadecahydro-1h-cyclopenta[a]phenanthren-16-yl)-1-allylpyrrolidinium Bromide
69. 1-[(2beta,3alpha,5alpha,16beta,17beta)-17-acetyloxy-3-hydroxy-2-(4-morpholinyl)-androstan-16-yl]-1(2-propenyl)pyrrolidinium Bromide
70. 1-[17beta-acetyloxy-3alpha-hydroxy-2beta-(4-morpholinyl)-5alpha-androstan-16beta-yl]-1-(2-propenyl)pyrrolidinium Bromide
71. 1-allyl-1-(3.alpha.,17.beta.-dihydroxy-2.beta.-morpholino-5.alpha.-androstan-16.beta.-yl)pyrrolidinium Bromide, 17-acetate
72. 17beta-(acetyloxy)-3alpha-hydroxy-2beta-(morpholin-4-yl)-16beta-[1-(prop-2-en-1-yl)pyrrolidinium-1-yl]-5alpha-androstane
73. 17beta-acetoxy-16beta-(1-allylpyrrolidinium-1-yl)-3alpha-hydroxy-2beta-(morpholin-4-yl)-5alphaandrostane
74. Pyrrolidinium, 1-((2.beta.,3.alpha.,5.alpha.,16.beta.,17.beta.)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)-, Bromide
Molecular Weight | 609.7 g/mol |
---|---|
Molecular Formula | C32H53BrN2O4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 6 |
Exact Mass | 608.31887 g/mol |
Monoisotopic Mass | 608.31887 g/mol |
Topological Polar Surface Area | 59 Ų |
Heavy Atom Count | 39 |
Formal Charge | 0 |
Complexity | 898 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 10 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Rocuronium bromide |
PubMed Health | Rocuronium (Injection) |
Drug Classes | Musculoskeletal Agent |
Drug Label | Rocuronium bromide injection is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. Rocuronium bromide USP is chemically designated as 1-[17-(acetyloxy)-3-hydroxy-2-(4-m... |
Active Ingredient | Rocuronium bromide |
Dosage Form | Injectable |
Route | Injection |
Strength | 50mg/5ml (10mg/ml); 100mg/10ml (10mg/ml) |
Market Status | Prescription |
Company | Sagent Strides; Hospira; Sandoz; Teva Pharms; Fresenius Kabi Usa; Tamarang; Mylan Institutional |
2 of 4 | |
---|---|
Drug Name | Zemuron |
Drug Label | ZEMURON (rocuronium bromide) injection is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. Rocuronium bromide is chemically designated as 1-[17-(acetyloxy)-3-hydroxy-2... |
Active Ingredient | Rocuronium bromide |
Dosage Form | Injectable |
Route | Injection |
Strength | 50mg/5ml (10mg/ml); 100mg/10ml (10mg/ml) |
Market Status | Prescription |
Company | Organon Usa |
3 of 4 | |
---|---|
Drug Name | Rocuronium bromide |
PubMed Health | Rocuronium (Injection) |
Drug Classes | Musculoskeletal Agent |
Drug Label | Rocuronium bromide injection is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. Rocuronium bromide USP is chemically designated as 1-[17-(acetyloxy)-3-hydroxy-2-(4-m... |
Active Ingredient | Rocuronium bromide |
Dosage Form | Injectable |
Route | Injection |
Strength | 50mg/5ml (10mg/ml); 100mg/10ml (10mg/ml) |
Market Status | Prescription |
Company | Sagent Strides; Hospira; Sandoz; Teva Pharms; Fresenius Kabi Usa; Tamarang; Mylan Institutional |
4 of 4 | |
---|---|
Drug Name | Zemuron |
Drug Label | ZEMURON (rocuronium bromide) injection is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. Rocuronium bromide is chemically designated as 1-[17-(acetyloxy)-3-hydroxy-2... |
Active Ingredient | Rocuronium bromide |
Dosage Form | Injectable |
Route | Injection |
Strength | 50mg/5ml (10mg/ml); 100mg/10ml (10mg/ml) |
Market Status | Prescription |
Company | Organon Usa |
Neuromuscular Nondepolarizing Agents
Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. (See all compounds classified as Neuromuscular Nondepolarizing Agents.)
M - Musculo-skeletal system
M03 - Muscle relaxants
M03A - Muscle relaxants, peripherally acting agents
M03AC - Other quaternary ammonium compounds
M03AC09 - Rocuronium bromide
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Rocuronium Bromide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rocuronium Bromide, including repackagers and relabelers. The FDA regulates Rocuronium Bromide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rocuronium Bromide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Rocuronium Bromide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Rocuronium Bromide supplier is an individual or a company that provides Rocuronium Bromide active pharmaceutical ingredient (API) or Rocuronium Bromide finished formulations upon request. The Rocuronium Bromide suppliers may include Rocuronium Bromide API manufacturers, exporters, distributors and traders.
click here to find a list of Rocuronium Bromide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Rocuronium Bromide DMF (Drug Master File) is a document detailing the whole manufacturing process of Rocuronium Bromide active pharmaceutical ingredient (API) in detail. Different forms of Rocuronium Bromide DMFs exist exist since differing nations have different regulations, such as Rocuronium Bromide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Rocuronium Bromide DMF submitted to regulatory agencies in the US is known as a USDMF. Rocuronium Bromide USDMF includes data on Rocuronium Bromide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Rocuronium Bromide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Rocuronium Bromide suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Rocuronium Bromide Drug Master File in Japan (Rocuronium Bromide JDMF) empowers Rocuronium Bromide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Rocuronium Bromide JDMF during the approval evaluation for pharmaceutical products. At the time of Rocuronium Bromide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Rocuronium Bromide suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Rocuronium Bromide Drug Master File in Korea (Rocuronium Bromide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Rocuronium Bromide. The MFDS reviews the Rocuronium Bromide KDMF as part of the drug registration process and uses the information provided in the Rocuronium Bromide KDMF to evaluate the safety and efficacy of the drug.
After submitting a Rocuronium Bromide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Rocuronium Bromide API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Rocuronium Bromide suppliers with KDMF on PharmaCompass.
A Rocuronium Bromide CEP of the European Pharmacopoeia monograph is often referred to as a Rocuronium Bromide Certificate of Suitability (COS). The purpose of a Rocuronium Bromide CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Rocuronium Bromide EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Rocuronium Bromide to their clients by showing that a Rocuronium Bromide CEP has been issued for it. The manufacturer submits a Rocuronium Bromide CEP (COS) as part of the market authorization procedure, and it takes on the role of a Rocuronium Bromide CEP holder for the record. Additionally, the data presented in the Rocuronium Bromide CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Rocuronium Bromide DMF.
A Rocuronium Bromide CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Rocuronium Bromide CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Rocuronium Bromide suppliers with CEP (COS) on PharmaCompass.
A Rocuronium Bromide written confirmation (Rocuronium Bromide WC) is an official document issued by a regulatory agency to a Rocuronium Bromide manufacturer, verifying that the manufacturing facility of a Rocuronium Bromide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Rocuronium Bromide APIs or Rocuronium Bromide finished pharmaceutical products to another nation, regulatory agencies frequently require a Rocuronium Bromide WC (written confirmation) as part of the regulatory process.
click here to find a list of Rocuronium Bromide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Rocuronium Bromide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Rocuronium Bromide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Rocuronium Bromide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Rocuronium Bromide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Rocuronium Bromide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Rocuronium Bromide suppliers with NDC on PharmaCompass.
Rocuronium Bromide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rocuronium Bromide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rocuronium Bromide GMP manufacturer or Rocuronium Bromide GMP API supplier for your needs.
A Rocuronium Bromide CoA (Certificate of Analysis) is a formal document that attests to Rocuronium Bromide's compliance with Rocuronium Bromide specifications and serves as a tool for batch-level quality control.
Rocuronium Bromide CoA mostly includes findings from lab analyses of a specific batch. For each Rocuronium Bromide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rocuronium Bromide may be tested according to a variety of international standards, such as European Pharmacopoeia (Rocuronium Bromide EP), Rocuronium Bromide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rocuronium Bromide USP).
LOOKING FOR A SUPPLIER?